Oncogenes in Primary Hepatic Cancer

1987 ◽  
pp. 50-57
Author(s):  
Gu Jian-Ren ◽  
Hu Li-Fu ◽  
Wan Da-Feng ◽  
Hong Jing-Xing
Keyword(s):  
Hepatic Cancer

Hepatic Cancer

1959 ◽  
Vol 37 (5) ◽  
pp. 669-688 ◽  
Author(s):  
W. Stanley Hartroft
Keyword(s):  
Hepatic Cancer

Advantage of microwave coagulo-necrotic therapy for hepatic cancer with chronic failure

1998 ◽  
Vol 16 ◽  
pp. 53-57
Author(s):  
Takatsugu Oida ◽  
Hiroshi Miyake ◽  
Shigeru Fujisaki ◽  
Ken-ichiro Mori ◽  
Satoshi Hata ◽  
...  
Keyword(s):  
Hepatic Cancer

Construction of recombinant adenovirus vectors containing Akt gene and its effect on survival of hepatic cancer cells

2012 ◽  
Vol 32 (3) ◽  
pp. 332-335
Author(s):  
Ke-he CHEN ◽  
Ze-long HAN ◽  
Jian-jun LI ◽  
Jin-fei PAN ◽  
An-ling LIU
Keyword(s):  
Cancer Cells ◽  
Recombinant Adenovirus ◽  
Hepatic Cancer ◽  
Adenovirus Vectors

scholarly journals Clinical application of thioredoxin reductase as a novel biomarker in liver cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Xuping Wu ◽  
Qi Wang ◽  
Yousheng Lu ◽  
Jinye Zhang ◽  
Hanwei Yin ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Tumor Markers ◽  
Clinical Application ◽  
Thioredoxin Reductase ◽  
Superior Performance ◽  
Percutaneous Ablation ◽  
Hepatic Cancer ◽  
Diagnostic Efficiency ◽  
Malignant Diseases ◽  
Clinical Method

AbstractHepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but it is likewise not always able to slow or halt progression, therefore novel approaches for treatment of hepatic cancer are needed. Current research suggests that molecular tumor markers (TM) can play a crucial role for diagnosis and prognostic evaluation of malignancies, and TM such as AFP, CEA, CA19-9 have been reported in many malignant diseases. Thioredoxin reductase (TrxR), a type of anti-oxidant biomarker, has become a TM of significant interest. However, little is known about the above TM and TrxR activity in liver cancer. Therefore, this paper aimed to assess these TM with regards to diagnosis and and monitoring treatment efficacy in both primary and metastatic liver cancer. Our results showed TrxR had superior performance for discriminating between liver cancer patients and healthy controls than AFP, CEA, and CA19-9. TrxR also exhibited superior performance for assessing benefits of chemotherapy regardless if patients had PLC or MLC. Meanwhile, due to diagnostic efficiency of unresponsive chemotherapy patients, TrxR also showed a higher activity levels than other general markers in liver metastasis patients. Our results suggest that application of TrxR in combination with other tumor markers may maximize the efficiency of diagnosis and assessment of therapeutic efficiency, and provide new insights for the clinical application of TrxR as a candidate biomarker for liver cancer.

scholarly journals The Protective Effect of Ammi visnaga Extract against Human Hepatic Cancer

2021 ◽  
pp. 101540
Author(s):  
Mohammed Waleed Arafah ◽  
Bader Almutairi ◽  
Mohammed Al-Zharani ◽  
Abdullah A. Alkahtane ◽  
Fatimah O. Al-Otibi ◽  
...  
Keyword(s):  
Protective Effect ◽  
Hepatic Cancer ◽  
Ammi Visnaga

scholarly journals Biology of hepatic cancer stem cells

2011 ◽  
Vol 26 (8) ◽  
pp. 1229-1237 ◽  
Author(s):  
Carol Man Tong ◽  
Stephanie Ma ◽  
Xin-Yuan Guan
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Hepatic Cancer
Sign in / Sign up

Export Citation Format

Share Document